Worsening disability progression in PPMS may be predicted by elevated levels of GFAP protein, a marker of damage in the brain, a study showed. buff.ly/3tLdfMT #news

Congratulations to Sergio Baranzini on being named the winner of the NMSS Barancik Prize for Innovation in MS Research. Dr. Baranzini serves on the ACTRIMS Program Committee and will receive the award and give the Prize Lecture at the #ACTRIMSForum 2024. nationalmssociety.org/About-the-Soci…

The plasma proteins that predict future dementia in healthy adults even more than 10 years before diagnosis, from >52,000 UK Biobank participants and assessment of >1,400 proteins (especially GFAP) nature.com/articles/s4358… Nature Aging

In a phase 2 trial involving participants with multiple sclerosis, the CD40L inhibitor frexalimab reduced the accumulation of new lesions on MRI at week 12 of treatment. Read the full trial results: nej.md/4bExZHa

@ThINk_Basel RC2NB University of Basel Departement Klinische Forschung, Universität Basel UniSpitalBaselCH

New work from my lab will be presented at @actrims by my postdoc Dr. Fumie Hayashi Fumie this Friday Mar 1 at 11 am. I won’t be able to attend the meeting, but I hope people will find it interesting. Please say hi to Fumie if you’re able to attend!

Let's keep moving! glad of the results of our analysis showing that leisure-time physical activity are beneficial for stroke prevention 🧠🏃🏻‍♂️🧠

Very excited to participate in this amazing workshop and discuss our approach and findings ECTRIMS

Dr. Ahmed Abdelhak award at #MSMilan2023 spotlights crucial advancements in #MS, and his study on #biomarkers opens new paths. Ready to make YOUR mark? #ECTRIMS2024 calls for your abstracts by 10 April! 📝 Submit now: bit.ly/3wmGzdA #Neurology #CallForAbstracts UC San Francisco

Multiple sclerosis endophenotypes identified by high-dimensional blood signatures are associated with distinct disease trajectories | Science Translational Medicine science.org/doi/10.1126/sc…

Blood test predicts MS in some ppl years before first symptoms, UC San Francisco scientists say. In 1/10 cases of MS, researchers found the body produces a 'distinctive' set of antibodies against its own proteins long before symptoms emerge. Study in Nature Medicine ucsf.edu/news/2024/04/4…

Tremendous milestone for precision medicine in MS. The autoantibody signature in a subpopulation of pwMS was present years before onset. Amazing work spearheaded by @ColinZamecnik, Gavin Sowa UC San Francisco out today in Nature Medicine …. Very proud to be part of it.

An antibody screen of two distinct Multiple Sclerosis cohorts reveals an autoantibody signature that is detectable years before symptom onset and linked to a common microbial motif Gavin Sowa, @ColinZamecnik, and Ahmed Abdelhak nature.com/articles/s4159…

🧠 Experts are meeting in Philadelphia to discuss #ageing and #MS at a workshop by the International Advisory Committe on Clinical Trials in MS, ECTRIMS & National MS Society. Learn more about this topic - join our webinar 🗓️ 30 April at 16:00 CEST. Register now! ➡️bit.ly/3Ukr1j5

Studying a patient with neurological deficits, scientists discovered autoantibodies against the #transcobalamin receptor CD320 that lead to #VitaminB12 deficiency in the central nervous system, but not in the blood. John Pluvinage UC San Francisco scim.ag/7wN

Press Release: HERCULES study demonstrates Tolebrutinib successfully delays disability in non-relapsing secondary progressive MS!

Check out our new study! ☑️p-tau 181 and 217 in blood are not as specific for AD as previously thought, ☑️they are also elevated in the blood of patients with ALS, ☑️IHC and MS analyses disclosed both p-tau species in muscle biopsies from ALS cases. nature.com/articles/s4146…

Chen et al. analysed gene expression in individuals with multiple sclerosis with differing remyelination capacities, identifying both known and novel remyelination-associated molecules. tinyurl.com/appxp8x4

"Biologically informative markers like #GFAP & #NfL may help predict confirmed disability worsening in #MultipleSclerosis. However, data on the prognostic value of their blood concentrations in #progressive MS are limited..." Ahmed Abdelhak et al doi.org/10.1136/jnnp-2…